Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies (Q104060011)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

9 December 2020

title

Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

9 December 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

9 December 2020

Davit Zohrabyan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

9 December 2020

Philip A Philip

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

9 December 2020

publication date

3 December 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

9 December 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

9 December 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Life expectancy in pancreatic neuroendocrine cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Whole-genome landscape of pancreatic neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

The neurofibromatosis type 1 gene and its protein product, neurofibromin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

MENIN loss as a tissue-specific driver of tumorigenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

High throughput gene sequencing reveals altered landscape in DNA damage responses and chromatin remodeling in sporadic pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Mutational heterogeneity in cancer and the search for new cancer-associated genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Characterization of the Neuroendocrine Tumor Immune Microenvironment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.33354

7 January 2021

Identifiers

DOI

10.1002/CNCR.33354

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json

9 December 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33270905%20AND%20SRC:MED&resulttype=core&format=json